Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of fluorouracil (5-FU),
levofolinate calcium (l-LV), oxaliplatin (L-OHP) and irinotecan hydrochloride hydrate
(CPT-11) (FOLFOXIRI) plus bevacizumab in untreated metastatic colorectal cancer patients who
harbor Uridine diphosphate (UDP)-glucuronosyl transferase 1A1 (UGT1A1) *1/*1, *1/*6 or
*1/*28.
Phase:
Phase 2
Details
Lead Sponsor:
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan Translational Research Informatics Center, Kobe, Hyogo, Japan
Collaborators:
Hiroshima Prefectural Hospital National Hospital Organization Shikoku Cancer Center